Equine Vaccination Protocols: Core and Risk-Based Vaccines

At a Glance

Core Vaccines: Essential Protection for All Horses

Core vaccines protect against diseases that pose significant health risks to horses regardless of geographic location or management practices. The American Association of Equine Practitioners (AAEP) defines core vaccines as those that should be administered to all horses, with few exceptions. These vaccines target diseases that are widely distributed, have high morbidity or mortality, or pose public health concerns. The Equids' Core Vaccines Guidelines in North America: Considerations and Prospective review published in Vaccines (2022) discusses the rationale for core vaccine recommendations based on disease epidemiology and vaccine efficacy data.

Tetanus Vaccine

Tetanus is caused by Clostridium tetani, a bacterium found in soil and manure that produces a potent neurotoxin. Horses are highly susceptible to tetanus due to their environment and tendency to sustain wounds. The tetanus vaccine is considered a core vaccine because the disease is invariably fatal in many cases and prevention is highly effective.

The tetanus toxoid vaccine provides reliable immunity when administered according to the manufacturer's label. Adult horses that have received an initial two-dose series require annual revaccination. For horses with unknown vaccination history, a primary series of two doses given 4 to 6 weeks apart is recommended, followed by an annual booster.

In wound management situations, horses that are not currently vaccinated or whose vaccination status is unknown may require tetanus antitoxin for immediate passive immunity. The Merck Veterinary Manual notes that tetanus antitoxin provides temporary protection but does not replace the need for active immunization with tetanus toxoid. Veterinary guidance is essential for determining the appropriate wound management protocol.

Eastern and Western Equine Encephalomyelitis (EEE/WEE)

Eastern equine encephalomyelitis (EEE) and Western equine encephalomyelitis (WEE) are mosquito-borne viral diseases that cause severe neurological signs in horses. EEE has a mortality rate exceeding 90% in horses, while WEE has a lower but still significant mortality rate. Both diseases are preventable through vaccination.

The EEE/WEE vaccine is typically combined with tetanus and sometimes West Nile virus in multivalent products. The AAEP recommends annual revaccination for adult horses, with the timing adjusted to occur before mosquito season in endemic areas. In regions with year-round mosquito activity, more frequent vaccination may be considered based on veterinary risk assessment.

Foals born to vaccinated mares receive maternal antibodies through colostrum, which can interfere with early vaccination. The Merck Veterinary Manual advises that foals should receive their initial EEE/WEE vaccination at 4 to 6 months of age, with a booster 4 to 6 weeks later, followed by annual revaccination.

Rabies Vaccine

Rabies is a fatal viral disease that affects the central nervous system of mammals, including horses. The disease is zoonotic, meaning it can be transmitted to humans, making rabies vaccination important for both animal and public health. Some jurisdictions require rabies vaccination for horses by law.

The rabies vaccine for horses is administered annually after an initial single dose. The AAEP includes rabies as a core vaccine because of the public health risk and the uniformly fatal outcome of the disease. Horses that have contact with wildlife or are kept in areas where rabies is endemic in wildlife populations face higher exposure risk.

Vaccination records should be maintained carefully, as proof of vaccination may be required for interstate travel or participation in events. The ACVIM provides guidelines on rabies vaccination and management of potential exposures.

West Nile Virus Vaccine

West Nile virus (WNV) is a mosquito-borne flavivirus that causes neurological disease in horses. Since its introduction to North America in 1999, WNV has become endemic across the continent. The disease has a mortality rate of 30 to 40% in horses showing clinical signs.

The WNV vaccine is available in both killed and recombinant formulations. The AAEP recommends annual revaccination for adult horses, with the timing optimized to provide peak immunity during mosquito season. In areas with prolonged mosquito seasons, semiannual vaccination may be considered.

Initial vaccination requires a two-dose series given 3 to 6 weeks apart, depending on the product. Foals should receive their first dose at 4 to 6 months of age, with a booster 4 to 6 weeks later. The Equids' Core Vaccines Guidelines in North America: Considerations and Prospective review published in Vaccines (2022) discusses the evolving recommendations for WNV vaccination based on regional disease patterns.

Risk-Based Vaccines: Tailored Protection Based on Exposure

Risk-based vaccines are recommended based on the individual horse's risk of exposure to specific diseases. Factors influencing risk include age, use, travel history, geographic location, and the disease status of other horses on the premises. The AAEP provides guidelines for risk assessment to help veterinarians and owners make informed decisions.

Equine Influenza Vaccine

Equine influenza is a highly contagious respiratory disease caused by influenza A viruses. The disease spreads rapidly among horses in group housing, at shows, and during transport. Clinical signs include fever, cough, nasal discharge, and lethargy.

The equine influenza vaccine is considered risk-based because not all horses face the same exposure risk. Horses that travel to shows, compete in events, or are housed in boarding facilities with frequent horse turnover are at higher risk. The AAEP recommends vaccination every 6 months for high-risk horses and annually for low-risk horses.

Vaccine efficacy can be affected by antigenic drift in circulating influenza strains. The World Organisation for Animal Health (WOAH) monitors equine influenza virus strains and provides recommendations for vaccine composition. The review "How to meet the last OIE expert surveillance panel recommendations on equine influenza (EI) vaccine composition" published in Pathogens (2016) discusses the process for updating vaccine strains to match circulating viruses.

Several vaccine types are available, including inactivated whole virus, subunit, and modified live vaccines. The review "Vaccines against equine influenza" published in Sel Skokhozyaistvennaya Biologiya (2019) provides an overview of available vaccine technologies and their immunogenicity profiles.

Vaccine failure can occur when the vaccine strain does not match the circulating virus or when the horse's immune response is inadequate. The study "Vaccine failure caused an outbreak of equine influenza in Croatia" published in Veterinary Microbiology (2009) documents an outbreak attributed to antigenic mismatch between the vaccine and the field virus.

The bivalent live-attenuated vaccine for equine influenza, described in the study published in Viruses (2019), represents a newer approach to influenza prevention. This vaccine type may provide broader protection against multiple strains.

Equine Herpesvirus (EHV) Vaccine

Equine herpesvirus type 1 (EHV-1) and type 4 (EHV-4) cause respiratory disease, abortion in pregnant mares, and neurological disease (equine herpesvirus myeloencephalopathy, EHM). EHV-1 is particularly concerning because of its potential to cause abortion storms and neurological outbreaks.

The EHV vaccine is risk-based and recommended for horses that travel, are housed in group settings, or are used for breeding. Pregnant mares should be vaccinated during the fifth, seventh, and ninth months of gestation to protect against EHV-1 abortion. The Merck Veterinary Manual provides specific guidance on vaccination schedules for broodmares.

For performance horses, vaccination every 6 months is common, with some veterinarians recommending more frequent vaccination during periods of high stress or travel. The ACVIM has published consensus statements on EHV-1 management, including vaccination recommendations.

Strangles Vaccine

Strangles, caused by Streptococcus equi subspecies equi, is a highly contagious bacterial infection of the upper respiratory tract and lymph nodes. The disease causes abscess formation in the lymph nodes of the head and neck, with potential for spread to other body sites (bastard strangles).

The strangles vaccine is risk-based and is not recommended for all horses. The AAEP advises that vaccination should be considered for horses at high risk of exposure, such as those in large boarding facilities, breeding farms, or areas where strangles is endemic. The vaccine is available in both modified live and killed formulations.

Vaccination decisions should be made in consultation with a veterinarian, as the vaccine can cause adverse reactions in some horses. The modified live vaccine is administered intranasally and may cause mild clinical signs in some horses. Horses with a history of purpura hemorrhagica, a complication of strangles, should not receive the vaccine.

Rotavirus Vaccine

Rotavirus is a leading cause of diarrhea in foals, particularly those between 1 and 4 weeks of age. The disease can cause significant morbidity and mortality in foal crops. The rotavirus vaccine is administered to pregnant mares to boost colostral antibody levels, providing passive immunity to foals.

The vaccine is risk-based and is recommended for breeding farms with a history of rotavirus diarrhea or where foals are at high risk. The AAEP recommends vaccinating mares during the eighth, ninth, and tenth months of gestation. The vaccine is not administered to foals directly.

Vaccination Schedules for Different Life Stages

Foals and Weanlings

Foals receive passive immunity through colostrum from vaccinated mares. Maternal antibodies can interfere with the foal's ability to respond to vaccination, so timing is critical. The Merck Veterinary Manual advises that foals should receive their first core vaccines at 4 to 6 months of age, depending on the vaccine and the level of maternal antibodies.

A typical foal vaccination schedule includes:

• 4 to 6 months: First dose of core vaccines (tetanus, EEE/WEE, West Nile)
• 5 to 7 months: Booster for core vaccines
• 6 to 8 months: Rabies vaccine (if indicated)
• 9 to 12 months: Annual booster for core vaccines

Risk-based vaccines for foals are determined by the veterinarian based on the farm's disease history and the foal's anticipated use. Influenza and EHV vaccines may be started at 6 to 9 months of age for foals that will enter training or travel.

Adult Horses

Adult horses with a history of regular vaccination require annual boosters for core vaccines. The AAEP recommends that core vaccines be administered annually, with the timing adjusted to provide protection before peak disease seasons.

For risk-based vaccines, the schedule depends on the horse's risk profile. High-risk horses, such as those that travel frequently or are housed in group settings, may require influenza and EHV vaccination every 6 months. Low-risk horses that are kept on private property with minimal horse contact may only require annual vaccination.

Pregnant Mares

Pregnant mares require special consideration to protect both the mare and the foal. The Merck Veterinary Manual recommends that mares be vaccinated against EHV-1 during the fifth, seventh, and ninth months of gestation to prevent abortion. Rotavirus vaccine is administered during the eighth, ninth, and tenth months of gestation to boost colostral antibodies.

Core vaccines should be administered to pregnant mares according to the standard schedule, with the timing adjusted to avoid vaccination during the first 60 days of gestation unless specifically recommended by a veterinarian. Vaccination during the last month of pregnancy is generally avoided to reduce the risk of adverse reactions.

Geriatric Horses

Geriatric horses (typically over 20 years of age) may have declining immune function, which can affect vaccine response. The AAEP recommends that geriatric horses continue to receive core vaccines annually. Some older horses may benefit from more frequent vaccination for risk-based diseases, particularly if they have underlying health conditions.

Veterinary assessment of the geriatric horse's overall health status is important before vaccination. Horses with chronic diseases such as pituitary pars intermedia dysfunction (PPID, equine Cushing's disease) may have altered immune responses and require adjusted vaccination protocols.

Vaccine Administration Techniques

Preparation and Handling

Vaccines must be handled according to the manufacturer's instructions to maintain potency. Most vaccines require refrigeration and protection from light. The Merck Veterinary Manual advises that vaccines should be inspected before use for discoloration, particulate matter, or damage to the vial.

The injection site should be clean and free of debris. For intramuscular injections, the neck muscles (splenius and semispinalis capitis) are the preferred site. The injection site should be alternated between vaccinations to reduce the risk of local reactions.

Injection Techniques

Intramuscular injections are the most common route for equine vaccines. The needle should be inserted at a 90-degree angle to the skin, and the plunger should be aspirated to confirm that the needle is not in a blood vessel. If blood appears in the syringe, the needle should be withdrawn and repositioned.

Intranasal vaccines, such as the modified live strangles vaccine, are administered using a specialized applicator. The vaccine is deposited into the nostril, and the horse should be restrained for a few seconds to allow the vaccine to be inhaled.

Subcutaneous injections are used for some vaccines, such as the rabies vaccine. The skin over the neck should be tented, and the needle inserted at a 45-degree angle.

Adverse Reactions

Adverse reactions to vaccination can occur, ranging from mild local swelling to severe systemic reactions. The AAEP advises that horses should be monitored for 30 to 60 minutes after vaccination for signs of anaphylaxis, including hives, respiratory distress, and collapse.

Local reactions, such as swelling or soreness at the injection site, are common and usually resolve within a few days. Cold compresses and nonsteroidal anti-inflammatory drugs (NSAIDs) may be used under veterinary guidance to manage discomfort.

Systemic reactions, including fever, lethargy, and decreased appetite, can occur within 24 to 48 hours of vaccination. These reactions are usually self-limiting but should be reported to the veterinarian.

Records and Measurements

Vaccination Records

Accurate vaccination records are essential for managing individual horse health and for compliance with event requirements. The AAEP recommends that records include:

• Horse identification (name, breed, age, color, markings)
• Date of vaccination
• Vaccine type and manufacturer
• Lot number and expiration date
• Route of administration and injection site
• Name and signature of the administrator
• Any adverse reactions observed

Records should be maintained for the life of the horse and transferred to new owners when the horse is sold. Digital record-keeping systems can help track vaccination schedules and send reminders for upcoming boosters.

Serological Monitoring

Serological testing can be used to assess antibody levels after vaccination, particularly for diseases such as equine influenza and EHV. The ACVIM provides guidelines on the use of serology in vaccination programs. Serological monitoring is not routinely recommended but may be useful in outbreak investigations or for horses with suspected vaccine failure.

Outbreak Investigation

When a disease outbreak occurs in a vaccinated population, investigation is warranted. The study "Vaccine failure caused an outbreak of equine influenza in Croatia" published in Veterinary Microbiology (2009) demonstrates the importance of investigating outbreaks to determine the cause, which may include vaccine failure, improper handling, or antigenic mismatch.

Common Failure Patterns

Improper Vaccine Handling

Vaccines that are not stored at the correct temperature or are exposed to light can lose potency. The Merck Veterinary Manual advises that vaccines should be stored at 2 to 8 degrees Celsius (35 to 46 degrees Fahrenheit) and protected from light. Freezing can damage some vaccines, while excessive heat can inactivate them.

Inadequate Vaccination Schedule

Failure to complete the initial vaccination series or to administer boosters on schedule can leave horses susceptible to disease. The AAEP emphasizes that the primary series must be completed according to the manufacturer's instructions to establish protective immunity.

Maternal Antibody Interference

Foals that receive high levels of maternal antibodies through colostrum may not respond adequately to early vaccination. The Merck Veterinary Manual advises that foals should not be vaccinated before 4 months of age for most core vaccines to allow maternal antibodies to wane.

Antigenic Mismatch

For diseases such as equine influenza, circulating virus strains can change over time. The World Organisation for Animal Health (WOAH) monitors equine influenza strains and provides recommendations for vaccine composition. When the vaccine strain does not match the circulating strain, vaccine efficacy may be reduced.

Welfare and Safety Context

Pain Management

Vaccination can cause discomfort, and appropriate handling techniques should be used to minimize stress. The AAEP recommends that horses be handled calmly and that injection sites be alternated to reduce the risk of local reactions.

Biosecurity

Vaccination is one component of a comprehensive biosecurity program. The World Organisation for Animal Health (WOAH) provides guidelines on biosecurity measures for equine facilities, including quarantine protocols for new horses and hygiene practices to reduce disease transmission.

Public Health

Rabies vaccination is important for public health because of the zoonotic potential of the disease. The ACVIM provides guidelines on rabies management, including postexposure prophylaxis for humans who have been exposed to potentially rabid animals.

Professional Escalation Criteria

Urgent Veterinary Consultation

Horses showing signs of an adverse vaccine reaction, including hives, respiratory distress, collapse, or severe local swelling, require immediate veterinary attention. Anaphylaxis can be life-threatening and requires prompt treatment with epinephrine and supportive care.

Routine Veterinary Consultation

Veterinary consultation is recommended for:

• Developing a vaccination schedule for a new horse or herd
• Managing horses with chronic diseases that may affect vaccine response
• Investigating suspected vaccine failure or disease outbreaks
• Determining the appropriate risk-based vaccines for individual horses
• Managing horses with a history of adverse vaccine reactions

Regulatory Considerations

Some jurisdictions require rabies vaccination for horses by law. The ACVIM provides information on state and local regulations regarding rabies vaccination. Veterinarians should be familiar with the requirements in their area and advise clients accordingly.

Practical Decision Framework for Equine Vaccination: A Risk-Based Prioritization and Implementation System

The Vaccination Decision Matrix: Balancing Risk, Cost, and Logistics

Managing equine vaccination programs requires a systematic approach that accounts for individual horse risk factors, facility characteristics, and operational constraints. The AAEP provides foundational guidelines, but translating these recommendations into daily farm management decisions demands a structured framework that farm managers and veterinarians can apply consistently. The Equids' Core Vaccines Guidelines in North America: Considerations and Prospective review published in Vaccines (2022) emphasizes that vaccination decisions should be based on disease epidemiology, vaccine efficacy data, and individual risk assessment instead of blanket protocols.

The Vaccination Decision Matrix presented here integrates three primary dimensions: disease consequence severity, exposure probability, and vaccine efficacy. Disease consequence severity considers mortality rates, morbidity duration, and potential for long-term complications. Exposure probability evaluates the likelihood of encountering the pathogen based on geographic location, horse movement patterns, and facility biosecurity. Vaccine efficacy accounts for the expected protection level based on product type, administration timing, and documented field performance.

For core vaccines, the decision matrix yields a consistent recommendation for all horses because the consequence severity is high and exposure probability is moderate to high across most North American regions. The Merck Veterinary Manual notes that tetanus carries a near-uniform fatality rate in horses, while EEE mortality exceeds 90%, justifying universal vaccination regardless of individual risk assessment.

For risk-based vaccines, the matrix produces variable recommendations. A show horse that travels weekly to events across multiple states faces high exposure probability for influenza and EHV, while a retired horse kept alone on a private farm with no outside horse contact faces low exposure probability. The decision matrix helps quantify these differences and supports targeted vaccination investment.

Step-by-Step Risk Assessment Protocol

Implementing a vaccination decision framework requires a repeatable assessment protocol that farm managers can execute with veterinary guidance. The following protocol uses observable, measurable criteria that do not require specialized diagnostic equipment.

Step 1: Classify Horse Movement Patterns

Record the number of horse movements per month, including competition attendance, trail rides, breeding visits, and veterinary clinic visits. Horses with more than two off-farm movements per month fall into the high-movement category. Horses with zero to one movement per month are low-movement. The Merck Veterinary Manual indicates that horses in high-movement categories face increased respiratory disease exposure risk.

Step 2: Assess Facility Horse Population Dynamics

Document the total number of horses on the premises and the monthly turnover rate. Facilities with more than 20 horses or with any horse leaving and returning within 30 days face higher disease introduction risk. Boarding facilities, training centers, and breeding farms typically fall into the high-population-dynamics category.

Step 3: Evaluate Geographic Disease Pressure

Consult with your veterinarian about regional disease prevalence data for EEE, WEE, West Nile virus, and strangles. The AAEP provides regional risk maps for mosquito-borne diseases. Areas with confirmed EEE cases in horses or mosquitoes within the past three years warrant heightened vaccination timing consideration.

Step 4: Determine Individual Horse Health Status

Record the horse's age, chronic disease conditions, and vaccination history. Horses over 20 years of age, horses with PPID (equine Cushing's disease), or horses with metabolic syndrome may have altered immune responses. The ACVIM provides guidance on vaccination in immunocompromised horses.

Step 5: Calculate Composite Risk Score

Assign points for each category: movement pattern (low=1, moderate=2, high=3), facility dynamics (low=1, moderate=2, high=3), geographic pressure (low=1, moderate=2, high=3), and health status (healthy=1, compromised=2). Horses scoring 4-6 points receive standard core vaccination with annual risk-based vaccines. Horses scoring 7-9 points receive core vaccination plus semiannual influenza and EHV vaccination. Horses scoring 10-12 points receive core vaccination plus semiannual influenza, EHV, and strangles vaccination with veterinary consultation.

Implementation Timeline and Seasonal Planning

Vaccination timing directly affects protection levels during peak disease seasons. The AAEP recommends that core vaccines be administered to provide peak immunity before disease season onset. For mosquito-borne diseases, this means completing the initial series or booster at least two weeks before mosquito activity begins in your region.

Spring Vaccination Window (March to May)

Administer EEE/WEE and West Nile virus vaccines during this window in most temperate North American regions. The Merck Veterinary Manual advises that horses in southern states with year-round mosquito activity may require different timing. Tetanus and rabies vaccines can be administered concurrently if the horse is due for annual boosters.

Fall Vaccination Window (September to November)

For horses on semiannual influenza and EHV schedules, administer boosters during this window. This timing provides protection through the winter show season and holiday travel periods when horse movement often increases.

Breeding Season Considerations

Pregnant mares require EHV-1 vaccination during the fifth, seventh, and ninth months of gestation to protect against abortion. The Merck Veterinary Manual provides specific guidance on this schedule. Rotavirus vaccination for mares occurs during the eighth, ninth, and tenth months of gestation to maximize colostral antibody transfer to foals.

Foal Vaccination Timing

Foals born to vaccinated mares receive maternal antibodies through colostrum, which can interfere with early vaccination response. The Merck Veterinary Manual advises that foals should receive their first core vaccines at 4 to 6 months of age, with the exact timing depending on maternal antibody levels. Foals from unvaccinated mares may benefit from earlier vaccination, but veterinary guidance is essential.

Record System for Vaccination Tracking and Compliance

A functional record system supports vaccination program success by ensuring timely boosters, documenting adverse reactions, and providing proof of vaccination for events and interstate travel. The AAEP recommends that records include horse identification, vaccination date, vaccine type and manufacturer, lot number, expiration date, route of administration, injection site, administrator name, and any adverse reactions observed.

Paper-Based Record System

Maintain individual horse vaccination records in a binder organized by horse name or barn number. Use a calendar system that shows upcoming vaccination due dates for the entire herd. Color-code entries by vaccine category: core vaccines in one color, risk-based vaccines in another. Include a separate section for adverse reaction reports with dates, signs observed, and veterinary contact information.

Digital Record System Options

Several equine management software platforms offer vaccination tracking features. These systems can generate automated reminders for upcoming boosters, store vaccine lot numbers for traceability, and produce vaccination certificates for events. The ACVIM notes that digital records facilitate rapid retrieval during disease outbreak investigations.

Minimum Record Elements for Legal Compliance

For rabies vaccination, some jurisdictions require specific documentation including the veterinarian's license number, vaccine manufacturer, and lot number. The ACVIM provides information on state and local regulations regarding rabies vaccination record requirements. Maintain these records for at least three years beyond the vaccination date.

Audit Protocol for Record Accuracy

Quarterly, review vaccination records against physical inventory of vaccine products used. Verify that lot numbers match between records and vaccine vials. Confirm that all horses have received core vaccines within the recommended interval. Flag any horses with overdue vaccinations for immediate veterinary consultation.

Troubleshooting Common Vaccination Program Failures

Even well-designed vaccination programs can experience failures. Identifying the root cause requires systematic investigation instead of assuming vaccine inefficacy. The study "Vaccine failure caused an outbreak of equine influenza in Croatia" published in Veterinary Microbiology (2009) documents how investigation revealed antigenic mismatch between the vaccine strain and the circulating field virus.

Cold Chain Breaks

Vaccines that are not stored at 2 to 8 degrees Celsius (35 to 46 degrees Fahrenheit) can lose potency. The Merck Veterinary Manual advises that vaccines should be inspected before use for discoloration, particulate matter, or damage to the vial. If a cold chain break is suspected, do not use the vaccine and contact the manufacturer for guidance.

Incorrect Administration Technique

Intramuscular injections must be placed in the neck muscles at a 90-degree angle to the skin. Aspiration before injection confirms that the needle is not in a blood vessel. Intranasal vaccines require proper deposition into the nostril with adequate restraint to ensure inhalation. Subcutaneous injections for rabies vaccine require tenting the skin over the neck.

Incomplete Primary Series

Horses that receive only one dose of a two-dose primary series may not develop protective immunity. The AAEP emphasizes that the primary series must be completed according to the manufacturer's instructions. If the interval between doses exceeds the recommended window, consult your veterinarian about restarting the series.

Maternal Antibody Interference

Foals vaccinated before maternal antibodies have waned may not mount an adequate immune response. The Merck Veterinary Manual advises that foals should not be vaccinated before 4 months of age for most core vaccines. If foals are vaccinated early due to high disease pressure, serological testing can assess antibody response.

Antigenic Drift in Circulating Strains

For equine influenza, circulating virus strains can change over time, potentially reducing vaccine efficacy. The World Organisation for Animal Health (WOAH) monitors equine influenza strains and provides recommendations for vaccine composition. The review "How to meet the last OIE expert surveillance panel recommendations on equine influenza (EI) vaccine composition" published in Pathogens (2016) discusses the process for updating vaccine strains.

Comparison of Vaccine Product Types and Their Practical Implications

Different vaccine technologies offer varying advantages and limitations that affect practical implementation on farms. Understanding these differences supports informed product selection in consultation with your veterinarian.

Killed (Inactivated) Vaccines

Killed vaccines contain inactivated pathogens that cannot cause disease. They require adjuvants to enhance immune response and typically need two doses for the primary series. The Merck Veterinary Manual notes that killed vaccines are generally safe for use in pregnant mares and immunocompromised horses. They require refrigeration and have a defined shelf life.

Modified Live Vaccines

Modified live vaccines contain weakened pathogens that replicate in the host without causing disease. They typically stimulate stronger cellular and humoral immunity than killed vaccines. The intranasal modified live strangles vaccine and some influenza vaccines fall into this category. These vaccines require careful handling to maintain viability and should not be used in immunocompromised horses.

Recombinant Vaccines

Recombinant vaccines use genetic engineering to produce specific antigens without using the whole pathogen. The canarypox-based West Nile virus vaccine is an example. The review "A bivalent live-attenuated vaccine for the prevention of equine influenza virus" published in Viruses (2019) describes recombinant approaches for influenza prevention. These vaccines may offer improved safety profiles and reduced adverse reactions.

Toxoid Vaccines

Toxoid vaccines use inactivated toxins instead of whole bacteria. The tetanus toxoid vaccine is the primary example. These vaccines stimulate antitoxin antibodies that neutralize the toxin instead of targeting the bacteria itself. The Merck Veterinary Manual notes that toxoid vaccines require boosters to maintain protective antibody levels.

Economic Analysis Framework for Vaccination Decisions

Vaccination programs require financial investment, and farm managers must balance costs against potential disease losses. A structured economic analysis supports informed resource allocation.

Direct Vaccination Costs

Calculate per-dose vaccine cost, administration supplies (needles, syringes, alcohol swabs), veterinary professional fees if applicable, and labor time for handling and restraint. Record these costs for each vaccine type and administration event.

Disease Outbreak Costs

Estimate potential costs of a disease outbreak including veterinary diagnostic fees, treatment medications, supportive care supplies, labor for isolation and monitoring, lost training or competition time, and potential mortality losses. The Merck Veterinary Manual provides information on disease-specific treatment costs.

Cost-Benefit Threshold

Compare annual vaccination costs against the probability of disease outbreak multiplied by estimated outbreak costs. For core vaccines with high disease consequence, the cost-benefit analysis consistently favors vaccination. For risk-based vaccines, the threshold varies based on individual horse risk factors.

Herd-Level Considerations

For breeding farms, vaccination costs for pregnant mares and foals should be evaluated against potential losses from abortion storms or foal diarrhea outbreaks. The rotavirus vaccine for pregnant mares, while adding cost, can significantly reduce foal morbidity and mortality on farms with endemic rotavirus.

Professional Escalation Criteria for Vaccination Program Issues

Certain situations require veterinary consultation beyond routine vaccination administration. Recognizing these situations supports timely intervention and prevents program failures.

Suspected Vaccine Failure

If a horse develops clinical signs of a disease for which it has been appropriately vaccinated, contact your veterinarian immediately. The study "Vaccine failure caused an outbreak of equine influenza in Croatia" published in Veterinary Microbiology (2009) demonstrates the importance of investigating outbreaks to determine the cause. Diagnostic testing can confirm the pathogen and assess whether the vaccine strain matches the field strain.

Adverse Reaction Clusters

If multiple horses on the same premises develop adverse reactions to the same vaccine lot, contact your veterinarian and the vaccine manufacturer. Document all reactions with dates, signs, and horse identification. The AAEP advises that adverse reaction reports help manufacturers monitor vaccine safety.

Changes in Regional Disease Patterns

If your veterinarian reports increased disease prevalence in your region, vaccination timing or frequency may need adjustment. The Equids' Core Vaccines Guidelines in North America: Considerations and Prospective review published in Vaccines (2022) discusses how regional disease patterns influence vaccination recommendations.

Introduction of New Horses to the Herd

New horses with unknown vaccination history require veterinary assessment to determine appropriate initial vaccination protocols. The Merck Veterinary Manual advises that horses with unknown history should receive a primary series for core vaccines instead of assuming prior immunity.

Regulatory Changes

If your jurisdiction changes rabies vaccination requirements or other vaccine-related regulations, consult your veterinarian to ensure compliance. The ACVIM provides information on state and local regulations regarding rabies vaccination.

Frequently Asked Questions

What is the difference between core and risk-based vaccines for horses?

Core vaccines are recommended for all horses regardless of location or use because they protect against diseases that are widely distributed, have high morbidity or mortality, or pose public health concerns. Risk-based vaccines are recommended based on the individual horse's risk of exposure, which is determined by factors such as age, use, travel history, and geographic location. The AAEP provides guidelines for both categories.

How often should horses receive core vaccines?

The AAEP recommends that adult horses receive core vaccines annually. The initial series for horses with unknown vaccination history requires two doses given 4 to 6 weeks apart, followed by an annual booster. The timing of vaccination should be adjusted to provide protection before peak disease seasons, such as before mosquito season for EEE/WEE and West Nile virus.

Can horses have adverse reactions to vaccines?

Yes, adverse reactions can occur, ranging from mild local swelling to severe systemic reactions. The AAEP advises that horses should be monitored for 30 to 60 minutes after vaccination for signs of anaphylaxis. Local reactions are common and usually resolve within a few days. Systemic reactions, including fever and lethargy, can occur within 24 to 48 hours and are usually self-limiting.

When should foals receive their first vaccines?

Foals should receive their first core vaccines at 4 to 6 months of age, depending on the vaccine and the level of maternal antibodies. The Merck Veterinary Manual advises that foals should not be vaccinated before 4 months of age for most core vaccines to allow maternal antibodies to wane. The initial series requires a booster 4 to 6 weeks after the first dose.

Is rabies vaccination required for horses?

Rabies vaccination is recommended as a core vaccine by the AAEP because of the public health risk and the uniformly fatal outcome of the disease. Some jurisdictions require rabies vaccination for horses by law. The ACVIM provides information on state and local regulations regarding rabies vaccination.

How does maternal antibody interference affect foal vaccination?

Maternal antibodies received through colostrum can interfere with the foal's ability to respond to vaccination. The Merck Veterinary Manual advises that foals should not be vaccinated before 4 months of age for most core vaccines to allow maternal antibodies to wane. The timing of vaccination may need to be adjusted based on the level of maternal antibodies in the foal.

What should be done if a horse misses a vaccine booster?

If a horse misses a vaccine booster, the veterinarian should be consulted to determine the appropriate course of action. For most vaccines, a single booster dose is sufficient if the interval since the last dose is not excessively long. If the interval is prolonged, the horse may need to restart the primary series.

How are equine influenza vaccine strains updated?

The World Organisation for Animal Health (WOAH) monitors equine influenza virus strains and provides recommendations for vaccine composition. The review "How to meet the last OIE expert surveillance panel recommendations on equine influenza (EI) vaccine composition" published in Pathogens (2016) discusses the process for updating vaccine strains to match circulating viruses. Vaccine manufacturers use these recommendations to update their products.

Related Veterinary Guides

• Veterinary Clinical Methods Procedures Surgical Interventions
• Working Equid Dental Care Routine Problem Management
• Broiler Respiratory Health Observation And Testing
• Mule Care Management Nutrition Housing Health
• Swine Respiratory Disease Observation And Diagnostics

References and Further Reading

• aaep.org
• www.merckvetmanual.com
• www.acvim.org
• Merck Veterinary Manual. Merck Veterinary Manual.
• Animal Health and Welfare. World Organisation for Animal Health.
• Equids' Core Vaccines Guidelines in North America: Considerations and Prospective.. Vaccines, 2022.
• How to meet the last oie expert surveillance panel recommendations on equine influenza (EI) vaccine composition: A review of the process required for the recombinant canarypox-based EI vaccine. Pathogens, 2016.
• Vaccines against equine influenza (review). Sel Skokhozyaistvennaya Biologiya, 2019.
• Vaccine failure caused an outbreak of equine influenza in Croatia. Veterinary Microbiology, 2009.
• A bivalent live-attenuated vaccine for the prevention of equine influenza virus. Viruses, 2019.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.